文献速递膀胱癌与上尿路尿路上皮癌前列腺增生与排尿功能障碍

膀胱肿瘤与前列腺增生同期内镜手术后的复发与进展风险:系统综述与荟萃分析

The recurrence and progression risk after simultaneous endoscopic surgery of urothelial bladder tumour and benign prostatic hyperplasia: a systematic review and meta-analysis.
PubMed 文献 · BJU Int · 2020-08-12

该系统综述与荟萃分析评估膀胱肿瘤与良性前列腺增生(BPH)同期内镜手术相比单纯经尿道膀胱肿瘤电切术(TURBT)的复发与进展风险。共纳入9项回顾性研究和3项临床试验,分别对回顾性研究和随机对照试验(RCT)进行荟萃分析。结果显示同期手术未增加总膀胱复发、膀胱颈/前列腺尿道(BN/PU)复发或肿瘤进展风险。

要点

  • 同期TURBT与TURP不增加BN/PU复发风险(回顾性RR 1.02,RCT RR 0.93)。
  • 同期手术不增加肿瘤进展风险(回顾性RR 0.91,RCT RR 1.16)。
  • 同期手术不增加总膀胱复发风险(回顾性RR 0.87,RCT RR 0.89)。

核心结论

  • 与单纯TURBT相比,膀胱肿瘤与BPH同期内镜手术未增加总膀胱复发、BN/PU复发或肿瘤进展风险。

研究设计与样本

  • 系统综述与荟萃分析,检索PubMed和Web of Science(2020年1月1日),纳入9项回顾性研究和3项临床试验。
  • 根据I2统计量选择随机效应或固定效应模型,分别对回顾性研究和RCT进行荟萃分析。

主要发现

  • BN/PU复发风险:8项回顾性研究汇总RR 1.02(95%CI 0.74-1.41),3项RCT汇总RR 0.93(95%CI 0.47-1.84)。
  • 进展风险:5项回顾性研究汇总RR 0.91(95%CI 0.56-1.48),2项RCT汇总RR 1.16(95%CI 0.30-4.51)。
  • 总膀胱复发风险:8项回顾性研究汇总RR 0.87(95%CI 0.78-0.97),3项RCT汇总RR 0.89(95%CI 0.65-1.21)。

临床怎么用

  • 对于合并BPH的膀胱肿瘤患者,同期行TURBT和TURP在肿瘤学安全性上可接受,不增加复发或进展风险。

局限性

  • 纳入研究多为回顾性设计,RCT数量有限,部分分析异质性及置信区间较宽。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate recurrence and progression risk after simultaneous endoscopic surgery of bladder cancer and benign prostatic hyperplasia (BPH), as simultaneous surgery is not an unusual scenario and theoretically simultaneous transurethral resection of bladder tumour (TURBT) and transurethral resection of the prostate (TURP) can lead to an increased risk of recurrence in the bladder neck and prostatic urethra (BN/PU). METHODS: We conducted a systematic review and meta-analysis to assess the risk of recurrence (i.e. whole bladder and/or BN/PU) and tumour progression as outcomes after a simultaneous endoscopic surgery of bladder tumour and BPH, as compared to TURBT alone. We queried PubMed and Web of Science database on 1 January 2020. We used random- and/or fixed-effects meta-analytic models in the presence or absence of heterogeneity according to the I2 statistic, respectively. RESULTS: Nine retrospective and three clinical trial studies were selected after considering inclusion and exclusion criteria. We conducted the meta-analysis on retrospective and randomised controlled trials (RCTs) separately. Eight retrospective and three RCT studies were included to assess the BN/PU recurrence risk and the summarised risk ratio (RR) was 1.02 (95% confidence interval [CI] 0.74-1.41) and 0.93 (95% CI 0.47-1.84), respectively. Five retrospective and two RCT studies were included to assess the progression risk and the summarised RR was 0.91 (95% CI 0.56-1.48) and 1.16 (95% CI 0.30-4.51), respectively. Eight retrospective and three RCT studies were included to assess the whole bladder recurrence risk and the summarised RR was 0.87 (95% CI 0.78-0.97) and 0.89 (95% CI 0.65-1.21), respectively. CONCLUSION: We did not observe any increased risk of total bladder recurrence, BN/PU recurrence, or progression after a simultaneous endoscopic surgery of bladder tumour and BPH, as compared to TURBT alone.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Sari Motlagh R, Mori K, Miura N, et al. The recurrence and progression risk after simultaneous endoscopic surgery of urothelial bladder tumour and benign prostatic hyperplasia: a systematic review and meta-analysis. BJU Int. 2020. PMID: 32564458. doi:10.1111/bju.15146

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。